Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site29.4.2025 14:00:00 CEST | Biomay AG | Press release
Vienna The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals.